Valneva SE (VALN) Receivables (2020 - 2026)
Valneva SE (VALN) posted quarterly Receivables of $11.5 million for Q1 2026, down 69.78% year-on-year from $38.1 million in Q1 2025, and down 63.57% on a QoQ basis from $31.6 million in Q4 2025.
Valneva SE (VALN) Receivables (2020 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Receivables for 7 consecutive years, with $11.5 million the latest figure, recorded in Q1 2026.
- Quarterly Receivables fell 69.78% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 69.78% YoY) and the FY2025 annual result came in at $31.6 million, down 21.0% from the prior year.
- Receivables declined to $11.5 million in Q1 2026 per VALN's latest filing, from $31.6 million in the prior quarter.
- Over the last five years, Receivables for VALN reached as high as $65.7 million in Q3 2022 and fell as low as $205969.7 in Q2 2023.
- A 5-year average of $31.8 million and a median of $31.0 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables plunged 98.89% — and 2024, when it jumped 16798.9%.
- Year by year, Receivables stood at $27.3 million in 2022, then surged by 73.54% to $47.4 million in 2023, then dropped by 15.46% to $40.1 million in 2024, then declined by 21.0% to $31.6 million in 2025, then slumped by 63.57% to $11.5 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $11.5 million, $31.6 million, and $22.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | 11.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.53 Mn |
| Dec 31, 2025 | 31.65 Mn |
| Sep 30, 2025 | 22.85 Mn |
| Jun 30, 2025 | 27.45 Mn |
| Mar 31, 2025 | 38.15 Mn |
| Dec 31, 2024 | 40.06 Mn |
| Sep 30, 2024 | 34.55 Mn |
| Jun 30, 2024 | 34.81 Mn |
| Mar 31, 2024 | 31.05 Mn |
| Dec 31, 2023 | 47.39 Mn |
| Sep 30, 2023 | 50.46 Mn |
| Jun 30, 2023 | 205,969.72 |
| Mar 31, 2023 | 30.75 Mn |
| Dec 31, 2022 | 27.31 Mn |
| Sep 30, 2022 | 65.70 Mn |
| Jun 30, 2022 | 18.50 Mn |
| Mar 31, 2022 | 28.52 Mn |
| Dec 31, 2021 | 50.08 Mn |
| Dec 31, 2020 | 21.89 Mn |